Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the
Zacks Style Scores, helps address this issue for us.
Below, we take a look at
Haemonetics (, which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. HAE Quick Quote HAE - Free Report)
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Haemonetics currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of
Zacks #1 Rank Stocks here >>> Set to Beat the Market?
Let's discuss some of the components of the Momentum Style Score for HAE that show why this provider blood management systems for health care providers and blood collectors shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For HAE, shares are up 4.21% over the past week while the Zacks Medical - Products industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 11.39% compares favorably with the industry's 7.51% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Haemonetics have risen 10.54%, and are up 100.82% in the last year. On the other hand, the S&P 500 has only moved 6.45% and -5.14%, respectively.
Investors should also take note of HAE's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, HAE is averaging 429,527 shares for the last 20 days.
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with HAE.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost HAE's consensus estimate, increasing from $2.86 to $2.87 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Taking into account all of these elements, it should come as no surprise that HAE is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Haemonetics on your short list.